류백렬 교수
#간암#담도암#췌장암#신경내분비종양
|
학력
2000 .03 ~ 2002 .02인제대학교 의학 박사
1998 .03 ~ 2000 .02단국대학교 의학 석사
1982 .03 ~ 1988 .02서울대학교 의학 학사
1998 .03 ~ 2000 .02단국대학교 의학 석사
1982 .03 ~ 1988 .02서울대학교 의학 학사
경력
2011 .09 ~ 현재서울아산병원 종양내과 교수
2009 .03 ~ 2011 .08서울아산병원 종양내과 부교수
1997 .03 ~ 2009 .02원자력병원 혈액종양내과 과장
1996 .03 ~ 1997 .02원자력병원 혈액종양내과 전임의
1992 .03 ~ 1996 .02원자력의학원 레지던트 (내과)
1991 .05 ~ 1992 .02서울아산병원 인턴
2009 .03 ~ 2011 .08서울아산병원 종양내과 부교수
1997 .03 ~ 2009 .02원자력병원 혈액종양내과 과장
1996 .03 ~ 1997 .02원자력병원 혈액종양내과 전임의
1992 .03 ~ 1996 .02원자력의학원 레지던트 (내과)
1991 .05 ~ 1992 .02서울아산병원 인턴
논문
Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer.
Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node
Metastasis.
A Phase I/IIa Study of DHP107, a Novel Oral Paclitaxel Formulation, in Patients with Advanced Solid Tumors or Gastric Cancer.
Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen
Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients.
Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing.
Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma.
Phase I/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XP ID) in advanced gastric cancer patients with peritoneal metastasis.
Postoperative Radiotherapy for Pancreatic Cancer with Microscopically-positive Resection Margin.
Prognostic Implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic Cholangiocarcinoma Treated with First-line Gemcitabine plus Cisplatin.
Prognostic Scoring Models for Patients Undergoing Sorafenib Treatment for Advanced Stage Hepatocellular Carcinoma in Real-Life Practice.
Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients.
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study.
Apoptosis of Hepatitis B Virus-expressing Liver Tumor Cells Induced by a High Concentration of Nucleos(t)ide Analogue.
Association of nutritional status-related indices and chemotherapy-induced adverse events in gastric cancer patients.
Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor After
Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program.
Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma: Potentially Improved Efficacy with Oxaliplatin-containing Regimen.
Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory
gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT).
Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers.
Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node
Metastasis.
A Phase I/IIa Study of DHP107, a Novel Oral Paclitaxel Formulation, in Patients with Advanced Solid Tumors or Gastric Cancer.
Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen
Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients.
Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing.
Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma.
Phase I/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XP ID) in advanced gastric cancer patients with peritoneal metastasis.
Postoperative Radiotherapy for Pancreatic Cancer with Microscopically-positive Resection Margin.
Prognostic Implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic Cholangiocarcinoma Treated with First-line Gemcitabine plus Cisplatin.
Prognostic Scoring Models for Patients Undergoing Sorafenib Treatment for Advanced Stage Hepatocellular Carcinoma in Real-Life Practice.
Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients.
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study.
Apoptosis of Hepatitis B Virus-expressing Liver Tumor Cells Induced by a High Concentration of Nucleos(t)ide Analogue.
Association of nutritional status-related indices and chemotherapy-induced adverse events in gastric cancer patients.
Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor After
Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program.
Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma: Potentially Improved Efficacy with Oxaliplatin-containing Regimen.
Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory
gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT).
Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers.
저서
환자를 위한 위장관 기질종양 치료지침서 제3판.
보도자료
서울아산병원 "말기 췌장암, 포기하지 마세요"
http://www.dailymedi.com/detail.php?number=842134&thread=22r03
서울아산병원 호스피탈리스트 만족도 '90점'
http://www.doctorsnews.co.kr/news/articleView.html?idxno=118138
초기증상 없는 췌장암, 발견 늦어도 항암 후 수술로 생존기간 연장
http://www.rapportian.com/news/articleView.html?idxno=121589
http://www.dailymedi.com/detail.php?number=842134&thread=22r03
서울아산병원 호스피탈리스트 만족도 '90점'
http://www.doctorsnews.co.kr/news/articleView.html?idxno=118138
초기증상 없는 췌장암, 발견 늦어도 항암 후 수술로 생존기간 연장
http://www.rapportian.com/news/articleView.html?idxno=121589
포스팅
Evaluation of genetic mutations and copy number alterations in biliary tract cancer using targeted exome sequencing
Phase 2 study of triplet chemotherapy with oxaliplatin, irinotecan and S-1 (OIS) as first-line treatment in patients with advanced biliary tract cancer (BTC)
Prognostic implications of hepatitis B virus infection in patients with intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin
Biomarker Analysis in Circulating Tumor DNA in Patients Treated with Sorafenib for Advanced Hepatocellular Carcinoma
Prognostic implications of hepatitis B virus infection in patients with intrahepatic cholangiocarcinoma treated with first-line gemcitabine / cisplatin
# 357 Clinical Benefit of Maintenance Therapy for Patients with Advanced Biliary Tract Cancer without
Progression on First-Line Gemcitabine plus Cisplatin
Multiplexed gene expression profiling of resected intrahepatic cholangiocarcinoma: Implication of FGFR4-FGF19 as a novel treatment target
Efficacy and Safety of Targeted agents for Treatment of Gastroenteropancreatic (GEP) Neuroendocrine tumor (NET): Single Center Experience
The prognostic impact of FGFR2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced gastric cancers
Efficacy of Chemotherapy in Patients with Pancreatic Acinar Cell Carcinoma
Clinical outcomes of patients with pancreatic neuroendocrine tumors treated with targeted agents: single center experience
Associations Between CYP2A6 Polymorphisms and Outcomes of Adjuvant S-1 Chemotherapy in Patients with Curatively Resected Gastric Cancer
Phase I/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XP ID) in patients with advanced gastric cancer with peritoneal metastasis
Phase II study of neoadjuvant chemotherapy with docetaxel, capecitabine, cisplatin and bevacizumab for initially unresectable gastric cancer with invasion of adjacent organs or paraaortic lymph node metastasis
Phase II study of neoadjuvant chemotherapy with docetaxel, capecitabine, cisplatin and bevacizumab for initially unresectable gastric cancer with invasion of adjacent organs or paraaortic lymph node metastasis
Phase II study of everolimus as a salvage treatment after failure of fluoropyrimidine and platinum in patients with metastatic gastric cancer positive for pS6Ser240/4 expression
Intraoperatively assessed macroscopic serosal changes in patients with curatively resected advanced gastric cancer: clinical implications for prognosis and peritoneal recurrence
Phase 2 study of triplet chemotherapy with oxaliplatin, irinotecan and S-1 (OIS) as first-line treatment in patients with advanced biliary tract cancer (BTC)
Prognostic implications of hepatitis B virus infection in patients with intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin
Biomarker Analysis in Circulating Tumor DNA in Patients Treated with Sorafenib for Advanced Hepatocellular Carcinoma
Prognostic implications of hepatitis B virus infection in patients with intrahepatic cholangiocarcinoma treated with first-line gemcitabine / cisplatin
# 357 Clinical Benefit of Maintenance Therapy for Patients with Advanced Biliary Tract Cancer without
Progression on First-Line Gemcitabine plus Cisplatin
Multiplexed gene expression profiling of resected intrahepatic cholangiocarcinoma: Implication of FGFR4-FGF19 as a novel treatment target
Efficacy and Safety of Targeted agents for Treatment of Gastroenteropancreatic (GEP) Neuroendocrine tumor (NET): Single Center Experience
The prognostic impact of FGFR2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced gastric cancers
Efficacy of Chemotherapy in Patients with Pancreatic Acinar Cell Carcinoma
Clinical outcomes of patients with pancreatic neuroendocrine tumors treated with targeted agents: single center experience
Associations Between CYP2A6 Polymorphisms and Outcomes of Adjuvant S-1 Chemotherapy in Patients with Curatively Resected Gastric Cancer
Phase I/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XP ID) in patients with advanced gastric cancer with peritoneal metastasis
Phase II study of neoadjuvant chemotherapy with docetaxel, capecitabine, cisplatin and bevacizumab for initially unresectable gastric cancer with invasion of adjacent organs or paraaortic lymph node metastasis
Phase II study of neoadjuvant chemotherapy with docetaxel, capecitabine, cisplatin and bevacizumab for initially unresectable gastric cancer with invasion of adjacent organs or paraaortic lymph node metastasis
Phase II study of everolimus as a salvage treatment after failure of fluoropyrimidine and platinum in patients with metastatic gastric cancer positive for pS6Ser240/4 expression
Intraoperatively assessed macroscopic serosal changes in patients with curatively resected advanced gastric cancer: clinical implications for prognosis and peritoneal recurrence
영상자료
영상자료 내용이 없습니다.
발표자료
A prospective study of repeat endoscopic biopsy to identify HER2- positive tumors following an initial HER2-negative biopsy in unresectable or metastatic gastric cancer: Gasther-1
A phase I/II study of DHP107, a novel oral paclitaxel formulation, in patients with advanced solid tumors (phase I) and gastric cancer (phaseII)
Phase II study of trastuzumab in combination with capecitabine and oxaliplatin in patients with advanced gastric cancer.
Incidence and risk factors of thromboembolism (TE) in advanced gastric cancer (AGC) receiving chemotherapy: A prospective observational study (NCT01047618)
A phase I dose escalation study to evaluate safety and tolerability of cabazitaxel (Cbz) as a single agent in patients (pts) with advanced gastric adenocarcinoma who have failed prior chemotherapy (CT) regimens
(GASTANA)
Randomized phase III trial of imatinib (IM) rechallenge versus placebo in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) after failure of at least both IM and sunitinib (SU): Right study
The role of surgical resection following imatinib treatment in patients with metastatic or recurrent GIST
A phase I dose finding study of everolimus in combination with capecitabine and oxaliplatin (XELOX) as the 1st line chemotherapy for patients with advanced gastric cancer
Five-year outcomes of a phase II study of adjuvant chemotherapy with docetaxel, capecitabine, and cisplatin in stage IIIB-IV(M0) gastric cancer patients
Phase III trial of a 3-weekly vs. 5-weekly schedule of S-1 plus cisplatin (SP) combination chemotherapy for first-line treatment of advanced gastric cancer (AGC): SOS study
Phase I study of vorinostat combined with capecitabine plus cisplatin as first-line chemotherapy in patients with advanced gastric cancer: The results of pharmacodynamic analysis
Phase III trial of a 3-weekly versus 5-weekly schedule of S-1 plus cisplatin (SP) combination chemotherapy for first-line treatment of advanced gastric cancer (AGC): SOS study
A phase I dose-finding study of vorinostat (V) combined with capecitabine (X) and cisplatin (P) as first-line therapy in patients with advanced gastric cancer
The role of surgical resection following imatinib treatment in patients with metastatic or recurrent GIST
Comparison of detection of FGFR2 amplification by quantitative real-time-PCR (qPCR) and fluorescent in situ hybridization (FISH) in gastric cancer
Phase III trial of a 3-weekly versus 5-weekly schedule of S-1 plus cisplatin (SP) combination chemotherapy for first-line treatment of advanced gastric cancer (AGC): SOS study
Safety and Feasibility of Adjuvant Chemotherapy with S-1 in Korean Patients with Curatively Resected Advanced Gastric Cancer
Update of AMC 0201 Study: A Randomized Phase III Trial Comparing Mitomycin-C plus Short-term
Doxifluridine (Mf) versus Mitomycin-C plus Long-term Doxifluridine plus Cisplatin (MFP) after Curative
Resection of Advanced Gastric Cancer (NCT00296335)
A phase II study of tivantinib monotherapy in patients with previously treated advanced or recurrent gastric cancer
Pharmacokinetics of escalated dose of imatinib in patients with advanced gastrointestinal stromal tumors
A phase I/II study of DHP107, a novel oral paclitaxel formulation, in patients with advanced solid tumors (phase I) and gastric cancer (phaseII)
Phase II study of trastuzumab in combination with capecitabine and oxaliplatin in patients with advanced gastric cancer.
Incidence and risk factors of thromboembolism (TE) in advanced gastric cancer (AGC) receiving chemotherapy: A prospective observational study (NCT01047618)
A phase I dose escalation study to evaluate safety and tolerability of cabazitaxel (Cbz) as a single agent in patients (pts) with advanced gastric adenocarcinoma who have failed prior chemotherapy (CT) regimens
(GASTANA)
Randomized phase III trial of imatinib (IM) rechallenge versus placebo in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) after failure of at least both IM and sunitinib (SU): Right study
The role of surgical resection following imatinib treatment in patients with metastatic or recurrent GIST
A phase I dose finding study of everolimus in combination with capecitabine and oxaliplatin (XELOX) as the 1st line chemotherapy for patients with advanced gastric cancer
Five-year outcomes of a phase II study of adjuvant chemotherapy with docetaxel, capecitabine, and cisplatin in stage IIIB-IV(M0) gastric cancer patients
Phase III trial of a 3-weekly vs. 5-weekly schedule of S-1 plus cisplatin (SP) combination chemotherapy for first-line treatment of advanced gastric cancer (AGC): SOS study
Phase I study of vorinostat combined with capecitabine plus cisplatin as first-line chemotherapy in patients with advanced gastric cancer: The results of pharmacodynamic analysis
Phase III trial of a 3-weekly versus 5-weekly schedule of S-1 plus cisplatin (SP) combination chemotherapy for first-line treatment of advanced gastric cancer (AGC): SOS study
A phase I dose-finding study of vorinostat (V) combined with capecitabine (X) and cisplatin (P) as first-line therapy in patients with advanced gastric cancer
The role of surgical resection following imatinib treatment in patients with metastatic or recurrent GIST
Comparison of detection of FGFR2 amplification by quantitative real-time-PCR (qPCR) and fluorescent in situ hybridization (FISH) in gastric cancer
Phase III trial of a 3-weekly versus 5-weekly schedule of S-1 plus cisplatin (SP) combination chemotherapy for first-line treatment of advanced gastric cancer (AGC): SOS study
Safety and Feasibility of Adjuvant Chemotherapy with S-1 in Korean Patients with Curatively Resected Advanced Gastric Cancer
Update of AMC 0201 Study: A Randomized Phase III Trial Comparing Mitomycin-C plus Short-term
Doxifluridine (Mf) versus Mitomycin-C plus Long-term Doxifluridine plus Cisplatin (MFP) after Curative
Resection of Advanced Gastric Cancer (NCT00296335)
A phase II study of tivantinib monotherapy in patients with previously treated advanced or recurrent gastric cancer
Pharmacokinetics of escalated dose of imatinib in patients with advanced gastrointestinal stromal tumors